ChP 2020, EP 9.0
- Valsartan-Sacubitril Sodium is a heart failure drug developed by Novartis Pharmaceuticals in the United States. Heart failure is a life-threatening debilitating disease.
- Valsartan-Sacubitril Sodium is a dual-acting angiotensin receptor enkephalinase inhibitor, developed by Novartis. It has a unique mode of action and is believed to reduce the strain of the failing heart.
-Valsartan-Sacubitril Sodium combines Novartis's hypertension drug valsartan and the experimental drug enkephalinase inhibitor AHU-377. AHU377 can block the mechanism of action that threatens the two polypeptides responsible for lowering blood pressure, while valsartan can improve vasodilation and stimulate the body to excrete sodium and water.
[ Disclaimer: The APIs are used for production of drug products. DO NOT USE DIRECTLY FOR PATIENTS. ]